<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nDr. Alin Nicolescu<\/strong><\/span>
Medic primar dermatovenerolog
Pre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii <\/strong><\/span><\/h4>\n <\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatment
Lectori: Daciana Branisteanu, Alin Nicolescu
<\/span><\/p>\nSimpozion Novartis: \u2019Terapia biologic\u0103 in UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!\u2019
Lectori: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu2<\/span>
1Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti
2Centrul Med. de Diagnostic si Tratament\u00a0 \u201cS.R.I.\u201d<\/p>\nCuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem<\/p>\n
Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.
Papulele \u0219i angioedemul sunt raportate in propor\u021bie de 33\u221267% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Datele cumulate de siguran\u021b\u0103 din studiile de faz\u0103 III demonstreaz\u0103 c\u0103 nu au existat diferente \u00eentre grupurile de tratament \u00een ceea ce prive\u0219te inciden\u021ba evenimentelor adverse.<\/p>\n
English version<\/span><\/span><\/span><\/p>\nKeywords: omalizumab, chronic spontaneous urticaria, hives, angioedema<\/p>\n
Chronic Spontaneous Urticaria is an intermittent chronic disease, characterized by the spontaneous appearance of hives and \/ or angioedema, every day or almost every day, for at least 6 weeks, without an obvious external factor.
Hives and angioedema are reported in 33\u221267% of patients with CSU, angioedema alone being present in only 1\u221213% of patients.
Symptomatic therapy with H1 antihistamines is the only first-line therapy in CSU, but the therapeutic effect is proven in less than 50% of patients with spontaneous chronic urticaria.
Omalizumab is indicated as add- on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years of age and older) patients, with inadequate response to H1 antihistamines.
The recommended dose is 300 mg subcutaneously at 4-weeks intervals.
In phase III studies (Asteria I, Asteria II, Glacial), Xolair consistently demonstrated significant improvements in CSU symptoms compared to placebo.
Cumulated safety data from phase III studies show that there were no differences between treatment groups in the incidence of adverse events.<\/p>\n
__________________________________________________________________________________<\/p>\n
Simpozion Abbvie: Redefinirea standardelor \u00een psoriazis: durabilitate, siguran\u021b\u0103, simplitate<\/span>
Lectori: Alin Nicolescu, Carmen Curea, Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriazisul este o boal\u0103 cronic\u0103, sistemic\u0103, cu un impact cumulativ asupra vie\u0163ii pacien\u021bilor.
Evolu\u021bia conceptelor fiziopatologice \u0219i cercetarea \u0219tiin\u021bific\u0103 au determinat dezvoltarea op\u021biunilor terapeutice \u00een psoriazis, ceea ce a dus la evolu\u021bia obiectivelor terapeutice \u0219i a standardelor de \u00eengrijire \u00een psoriazis.
Optiunile terapeutice ap\u0103rute \u00een ultimii ani, care \u021bintesc citokine cheie (ex. IL-23), au poten\u021bialul de a \u00eembun\u0103t\u0103\u021bi standardele de \u00eengrijire pentru pacien\u021bii cu psoriazis.
Odat\u0103 cu progresele ob\u021binute \u00een managementul psoriazisului moderat-sever, acum pot fi atinse obiective terapeutice mai \u00eenalte, iar pacien\u021bii pot avea a\u0219tept\u0103ri mai mari de la tratamentul pe care \u00eel urmeaz\u0103.
SKYRIZI\u00ae (Risankizumab) este un anticorp monoclonal umanizat care se leag\u0103 \u00een mod specific de subunitatea p19 a IL-23. SKYRIZI\u00ae a demonstrat \u00een studiile clinice ob\u021binerea unor niveluri \u00eenalte de cur\u0103\u0163are a leziunilor de psoriazis, men\u0163inerea eficacit\u0103\u0163ii tratamentului \u00een timp, cu un profil de siguran\u021b\u0103 favorabil pe termen lung, av\u00e2nd o schem\u0103 de administrare convenabil\u0103.
Ob\u021binerea unei cur\u0103\u021b\u0103ri cutanate complete poate reduce semnificativ povara pe care pacien\u021bii cu psoriazis moderat-sever o resimt pe termen lung.
Datele de eficacitate \u0219i siguran\u021b\u0103 din studiile clinice cu risankizumab demonstreaz\u0103 c\u0103 medicii \u0219i pacien\u021bii \u00ee\u0219i pot propune \u0219i ob\u021bine obiective terapeutice \u00eenalte.
De la studii clinice la practica clinic\u0103 se vor g\u0103si r\u0103spunsurile la \u00eentrebarea: De ce Skyrizi este o op\u021biune pentru pacien\u021bii cu psoriazis?<\/p>\n
_______________________________________________________________________________<\/p>\n
Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica<\/span>
Lectori: Daciana Elena Br\u0103ni\u0219teanu, C\u0103lin Giurc\u0103neanu, Alin Nicolescu<\/span><\/p>\nDA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata cauza a dermatitei atopice este inflamatia de Tip2\/Th2 iar IL4 si IL13 sunt citokinele cheie implicate in mecanismul imunologic.
Dupixent este prima terapie biologica aprobata pentru tratamentul dermatitei atopice cu forma moderata pana la severa. Dupixent este un anticorp monoclonal uman care se leaga specific de receptorul alfa al interleukinei 4 (IL-4) si inhiba semnalizarea celulara a IL4\/IL13. Dupixent a demonstrat imbunatatiri rapide si sustinute ale semnelor si simptomelor DA precum si a calitatii vietii la adulti cu DA moderat-severa. Dupixent a demonstrate un profil de siguranta favorabil la adulti cu DA moderat-severa.<\/p>\n
English version<\/span>
<\/span><\/span><\/p>\nAtopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism.
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
Scurt CV<\/span><\/p>\nDr. Alin Nicolescu este medic primar dermatovenerolog \u0219i Pre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii. A urmat numeroase cursuri de specializare \u00een \u0163ar\u0103 \u015fi str\u0103in\u0103tate pentru Laser Nd-Yag, dermatoscopie, ecografie cutanat\u0103, printre care:
\u2022 curs de Ecografie cutanat\u0103 \u2013 \u201eCortex Technologz\u201d (1996)
\u2022 curs de Ecografie cutanat\u0103 la Viena (1996)
\u2022 curs de Dermatoscopie la LKH Gratz (1996)
\u2022 curs Pulsed Dye Laser \u00een Viena (1996)
\u2022 curs de lasere (CO2, PDL, Nd Yag, Dioda) la Tel Aviv, Israel (1997)
\u2022 curs de lasere, CO2, Scanner \u00een Israel, Haifa (1997)
\u2022 curs Pulsed Dye Laser, Nd-Yag, Compania Coherent (2008)
\u2022 programul de Lasere \u00een Medicin\u0103 SPIRALMED (2010).
Autor al peste 200 de lucr\u0103ri publicate \u015fi comunicate din \u0163ar\u0103 \u015fi str\u0103in\u0103tate. Colaborator la redactarea manualului \u201cDermato-venerologie 2000\u201d.Consultant de specialitate pentru diverse afec\u0163iuni (dermatita atopic\u0103, psoriazis, etc.) \u00een cadrul cursurilor organizate de diverse companii farmaceutice.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Alin NicolescuMedic primar dermatovenerologPre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatmentLectori: Daciana Branisteanu, Alin Nicolescu Simpozion Novartis: \u2019Terapia biologic\u0103 in UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!\u2019Lectori: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu21Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9872","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9872"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872\/revisions"}],"predecessor-version":[{"id":10397,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872\/revisions\/10397"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Dr. Alin Nicolescu<\/strong><\/span>
Medic primar dermatovenerolog
Pre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii <\/strong><\/span><\/h4>\n <\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″ locked=”off”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatment
Lectori: Daciana Branisteanu, Alin Nicolescu
<\/span><\/p>\nSimpozion Novartis: \u2019Terapia biologic\u0103 in UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!\u2019
Lectori: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu2<\/span>
1Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti
2Centrul Med. de Diagnostic si Tratament\u00a0 \u201cS.R.I.\u201d<\/p>\nCuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem<\/p>\n
Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident.
Papulele \u0219i angioedemul sunt raportate in propor\u021bie de 33\u221267% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Datele cumulate de siguran\u021b\u0103 din studiile de faz\u0103 III demonstreaz\u0103 c\u0103 nu au existat diferente \u00eentre grupurile de tratament \u00een ceea ce prive\u0219te inciden\u021ba evenimentelor adverse.<\/p>\n
English version<\/span><\/span><\/span><\/p>\nKeywords: omalizumab, chronic spontaneous urticaria, hives, angioedema<\/p>\n
Chronic Spontaneous Urticaria is an intermittent chronic disease, characterized by the spontaneous appearance of hives and \/ or angioedema, every day or almost every day, for at least 6 weeks, without an obvious external factor.
Hives and angioedema are reported in 33\u221267% of patients with CSU, angioedema alone being present in only 1\u221213% of patients.
Symptomatic therapy with H1 antihistamines is the only first-line therapy in CSU, but the therapeutic effect is proven in less than 50% of patients with spontaneous chronic urticaria.
Omalizumab is indicated as add- on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years of age and older) patients, with inadequate response to H1 antihistamines.
The recommended dose is 300 mg subcutaneously at 4-weeks intervals.
In phase III studies (Asteria I, Asteria II, Glacial), Xolair consistently demonstrated significant improvements in CSU symptoms compared to placebo.
Cumulated safety data from phase III studies show that there were no differences between treatment groups in the incidence of adverse events.<\/p>\n
__________________________________________________________________________________<\/p>\n
Simpozion Abbvie: Redefinirea standardelor \u00een psoriazis: durabilitate, siguran\u021b\u0103, simplitate<\/span>
Lectori: Alin Nicolescu, Carmen Curea, Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\nPsoriazisul este o boal\u0103 cronic\u0103, sistemic\u0103, cu un impact cumulativ asupra vie\u0163ii pacien\u021bilor.
Evolu\u021bia conceptelor fiziopatologice \u0219i cercetarea \u0219tiin\u021bific\u0103 au determinat dezvoltarea op\u021biunilor terapeutice \u00een psoriazis, ceea ce a dus la evolu\u021bia obiectivelor terapeutice \u0219i a standardelor de \u00eengrijire \u00een psoriazis.
Optiunile terapeutice ap\u0103rute \u00een ultimii ani, care \u021bintesc citokine cheie (ex. IL-23), au poten\u021bialul de a \u00eembun\u0103t\u0103\u021bi standardele de \u00eengrijire pentru pacien\u021bii cu psoriazis.
Odat\u0103 cu progresele ob\u021binute \u00een managementul psoriazisului moderat-sever, acum pot fi atinse obiective terapeutice mai \u00eenalte, iar pacien\u021bii pot avea a\u0219tept\u0103ri mai mari de la tratamentul pe care \u00eel urmeaz\u0103.
SKYRIZI\u00ae (Risankizumab) este un anticorp monoclonal umanizat care se leag\u0103 \u00een mod specific de subunitatea p19 a IL-23. SKYRIZI\u00ae a demonstrat \u00een studiile clinice ob\u021binerea unor niveluri \u00eenalte de cur\u0103\u0163are a leziunilor de psoriazis, men\u0163inerea eficacit\u0103\u0163ii tratamentului \u00een timp, cu un profil de siguran\u021b\u0103 favorabil pe termen lung, av\u00e2nd o schem\u0103 de administrare convenabil\u0103.
Ob\u021binerea unei cur\u0103\u021b\u0103ri cutanate complete poate reduce semnificativ povara pe care pacien\u021bii cu psoriazis moderat-sever o resimt pe termen lung.
Datele de eficacitate \u0219i siguran\u021b\u0103 din studiile clinice cu risankizumab demonstreaz\u0103 c\u0103 medicii \u0219i pacien\u021bii \u00ee\u0219i pot propune \u0219i ob\u021bine obiective terapeutice \u00eenalte.
De la studii clinice la practica clinic\u0103 se vor g\u0103si r\u0103spunsurile la \u00eentrebarea: De ce Skyrizi este o op\u021biune pentru pacien\u021bii cu psoriazis?<\/p>\n
_______________________________________________________________________________<\/p>\n
Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica<\/span>
Lectori: Daciana Elena Br\u0103ni\u0219teanu, C\u0103lin Giurc\u0103neanu, Alin Nicolescu<\/span><\/p>\nDA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata cauza a dermatitei atopice este inflamatia de Tip2\/Th2 iar IL4 si IL13 sunt citokinele cheie implicate in mecanismul imunologic.
Dupixent este prima terapie biologica aprobata pentru tratamentul dermatitei atopice cu forma moderata pana la severa. Dupixent este un anticorp monoclonal uman care se leaga specific de receptorul alfa al interleukinei 4 (IL-4) si inhiba semnalizarea celulara a IL4\/IL13. Dupixent a demonstrat imbunatatiri rapide si sustinute ale semnelor si simptomelor DA precum si a calitatii vietii la adulti cu DA moderat-severa. Dupixent a demonstrate un profil de siguranta favorabil la adulti cu DA moderat-severa.<\/p>\n
English version<\/span>
<\/span><\/span><\/p>\nAtopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism.
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
Scurt CV<\/span><\/p>\nDr. Alin Nicolescu este medic primar dermatovenerolog \u0219i Pre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii. A urmat numeroase cursuri de specializare \u00een \u0163ar\u0103 \u015fi str\u0103in\u0103tate pentru Laser Nd-Yag, dermatoscopie, ecografie cutanat\u0103, printre care:
\u2022 curs de Ecografie cutanat\u0103 \u2013 \u201eCortex Technologz\u201d (1996)
\u2022 curs de Ecografie cutanat\u0103 la Viena (1996)
\u2022 curs de Dermatoscopie la LKH Gratz (1996)
\u2022 curs Pulsed Dye Laser \u00een Viena (1996)
\u2022 curs de lasere (CO2, PDL, Nd Yag, Dioda) la Tel Aviv, Israel (1997)
\u2022 curs de lasere, CO2, Scanner \u00een Israel, Haifa (1997)
\u2022 curs Pulsed Dye Laser, Nd-Yag, Compania Coherent (2008)
\u2022 programul de Lasere \u00een Medicin\u0103 SPIRALMED (2010).
Autor al peste 200 de lucr\u0103ri publicate \u015fi comunicate din \u0163ar\u0103 \u015fi str\u0103in\u0103tate. Colaborator la redactarea manualului \u201cDermato-venerologie 2000\u201d.Consultant de specialitate pentru diverse afec\u0163iuni (dermatita atopic\u0103, psoriazis, etc.) \u00een cadrul cursurilor organizate de diverse companii farmaceutice.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n
Contacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Dr. Alin NicolescuMedic primar dermatovenerologPre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatmentLectori: Daciana Branisteanu, Alin Nicolescu Simpozion Novartis: \u2019Terapia biologic\u0103 in UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!\u2019Lectori: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu21Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9872","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9872"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872\/revisions"}],"predecessor-version":[{"id":10397,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872\/revisions\/10397"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Lectori: Daciana Branisteanu, Alin Nicolescu
<\/span><\/p>\n
Simpozion Novartis: \u2019Terapia biologic\u0103 in UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!\u2019 Cuvinte cheie: omalizumab, urticarie cronic\u0103 spontan\u0103, papule, angioedem<\/p>\n Urticaria Cronic\u0103 Spontan\u0103 este o afec\u021biune cronic\u0103 intermitent\u0103, caracterizat\u0103 prin apari\u021bia spontan\u0103 a papulelor sau\/\u0219i a angioedemului, in fiecare zi sau aproape in toate zilele, pentru cel pu\u021bin 6 s\u0103pt\u0103m\u00e2ni, f\u0103r\u0103 un stimul extern evident. English version<\/span><\/span><\/span><\/p>\n Keywords: omalizumab, chronic spontaneous urticaria, hives, angioedema<\/p>\n Chronic Spontaneous Urticaria is an intermittent chronic disease, characterized by the spontaneous appearance of hives and \/ or angioedema, every day or almost every day, for at least 6 weeks, without an obvious external factor. __________________________________________________________________________________<\/p>\n Simpozion Abbvie: Redefinirea standardelor \u00een psoriazis: durabilitate, siguran\u021b\u0103, simplitate<\/span> Psoriazisul este o boal\u0103 cronic\u0103, sistemic\u0103, cu un impact cumulativ asupra vie\u0163ii pacien\u021bilor. _______________________________________________________________________________<\/p>\n Simpozion Sanofi: Dupilumab \u2013 primul imunomodulator in Dermatita Atopica<\/span> DA este o boala inflamatorie cronica sistemica si nu doar o bolala de piele intermitenta, asa cum era considerata in trecut, caracterizata prin prurit intens si leziuni eczematoase. Adevarata cauza a dermatitei atopice este inflamatia de Tip2\/Th2 iar IL4 si IL13 sunt citokinele cheie implicate in mecanismul imunologic. English version<\/span> Atopic Dermatitis is an inflammatory chronic disease, characterized by intense pruritus and eczematous lesions, it is not just an intermittent skin disease as it was considered in the past. The root cause of atopic dermatitis is Type 2\/Th 2 inflammation and IL4 and IL3 are the main cytokines involved in the immune mechanism. Scurt CV<\/span><\/p>\n Dr. Alin Nicolescu este medic primar dermatovenerolog \u0219i Pre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii. A urmat numeroase cursuri de specializare \u00een \u0163ar\u0103 \u015fi str\u0103in\u0103tate pentru Laser Nd-Yag, dermatoscopie, ecografie cutanat\u0103, printre care: [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” global_module=”9177″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n Contacteaz\u0103 operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464,10156,10157″ fullwidth=”on” _builder_version=”4.9.7″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Dr. Alin NicolescuMedic primar dermatovenerologPre\u0219edintele Comisiei de Dermatovenerologie a Ministerului S\u0103n\u0103t\u0103\u021bii Simpozion Novartis: All about the patient \u2013 A dialogue about importance of patient evaluation and adherence to the treatmentLectori: Daciana Branisteanu, Alin Nicolescu Simpozion Novartis: \u2019Terapia biologic\u0103 in UCS \u2013 o solu\u021bie pentru pacient \u0219i medic!\u2019Lectori: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu21Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-9872","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=9872"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872\/revisions"}],"predecessor-version":[{"id":10397,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/9872\/revisions\/10397"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=9872"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Lectori: C\u0103lin Giurc\u0103neanu1, Alin Nicolescu2<\/span>
1Spitalul Universitar de Urgent\u0103 \u201dElias\u201d, Bucure\u0219ti
2Centrul Med. de Diagnostic si Tratament\u00a0 \u201cS.R.I.\u201d<\/p>\n
Papulele \u0219i angioedemul sunt raportate in propor\u021bie de 33\u221267% la pacien\u021bii cu UCS, angioedemul singur fiind prezent doar la 1\u221213% din pacien\u021bi.
Terapia simptomatic\u0103 cu antihistaminice H1 este singura terapie de prim\u0103 inten\u021bie in UCS, dar efectul terapeutic este dovedit la mai pu\u021bin de 50 % dintre pacien\u021bii cu urticarie cronic\u0103 spontan\u0103
Omalizumab este indicat ca tratament adjuvant al UCS la pacien\u0163i adul\u0163i \u015fi adolescen\u0163i (12 ani \u0219i peste) cu r\u0103spuns neadecvat la tratamentul cu antihistaminice H1.
Doza recomandat\u0103 este de 300 mg, subcutanat, la intervale de 4 s\u0103pt\u0103m\u00e2ni.
\u00cen studiile de faz\u0103 III (Asteria I, Asteria II, Glacial) omalizumab administrat in doz\u0103 de 300 mg a demonstrat \u00een mod constant \u00eembunata\u021biri semnificative ale simptomelor UCS \u00een compara\u021bie cu placebo.
Datele cumulate de siguran\u021b\u0103 din studiile de faz\u0103 III demonstreaz\u0103 c\u0103 nu au existat diferente \u00eentre grupurile de tratament \u00een ceea ce prive\u0219te inciden\u021ba evenimentelor adverse.<\/p>\n
Hives and angioedema are reported in 33\u221267% of patients with CSU, angioedema alone being present in only 1\u221213% of patients.
Symptomatic therapy with H1 antihistamines is the only first-line therapy in CSU, but the therapeutic effect is proven in less than 50% of patients with spontaneous chronic urticaria.
Omalizumab is indicated as add- on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years of age and older) patients, with inadequate response to H1 antihistamines.
The recommended dose is 300 mg subcutaneously at 4-weeks intervals.
In phase III studies (Asteria I, Asteria II, Glacial), Xolair consistently demonstrated significant improvements in CSU symptoms compared to placebo.
Cumulated safety data from phase III studies show that there were no differences between treatment groups in the incidence of adverse events.<\/p>\n
Lectori: Alin Nicolescu, Carmen Curea, Daciana Elena Br\u0103ni\u0219teanu<\/span><\/p>\n
Evolu\u021bia conceptelor fiziopatologice \u0219i cercetarea \u0219tiin\u021bific\u0103 au determinat dezvoltarea op\u021biunilor terapeutice \u00een psoriazis, ceea ce a dus la evolu\u021bia obiectivelor terapeutice \u0219i a standardelor de \u00eengrijire \u00een psoriazis.
Optiunile terapeutice ap\u0103rute \u00een ultimii ani, care \u021bintesc citokine cheie (ex. IL-23), au poten\u021bialul de a \u00eembun\u0103t\u0103\u021bi standardele de \u00eengrijire pentru pacien\u021bii cu psoriazis.
Odat\u0103 cu progresele ob\u021binute \u00een managementul psoriazisului moderat-sever, acum pot fi atinse obiective terapeutice mai \u00eenalte, iar pacien\u021bii pot avea a\u0219tept\u0103ri mai mari de la tratamentul pe care \u00eel urmeaz\u0103.
SKYRIZI\u00ae (Risankizumab) este un anticorp monoclonal umanizat care se leag\u0103 \u00een mod specific de subunitatea p19 a IL-23. SKYRIZI\u00ae a demonstrat \u00een studiile clinice ob\u021binerea unor niveluri \u00eenalte de cur\u0103\u0163are a leziunilor de psoriazis, men\u0163inerea eficacit\u0103\u0163ii tratamentului \u00een timp, cu un profil de siguran\u021b\u0103 favorabil pe termen lung, av\u00e2nd o schem\u0103 de administrare convenabil\u0103.
Ob\u021binerea unei cur\u0103\u021b\u0103ri cutanate complete poate reduce semnificativ povara pe care pacien\u021bii cu psoriazis moderat-sever o resimt pe termen lung.
Datele de eficacitate \u0219i siguran\u021b\u0103 din studiile clinice cu risankizumab demonstreaz\u0103 c\u0103 medicii \u0219i pacien\u021bii \u00ee\u0219i pot propune \u0219i ob\u021bine obiective terapeutice \u00eenalte.
De la studii clinice la practica clinic\u0103 se vor g\u0103si r\u0103spunsurile la \u00eentrebarea: De ce Skyrizi este o op\u021biune pentru pacien\u021bii cu psoriazis?<\/p>\n
Lectori: Daciana Elena Br\u0103ni\u0219teanu, C\u0103lin Giurc\u0103neanu, Alin Nicolescu<\/span><\/p>\n
Dupixent este prima terapie biologica aprobata pentru tratamentul dermatitei atopice cu forma moderata pana la severa. Dupixent este un anticorp monoclonal uman care se leaga specific de receptorul alfa al interleukinei 4 (IL-4) si inhiba semnalizarea celulara a IL4\/IL13. Dupixent a demonstrat imbunatatiri rapide si sustinute ale semnelor si simptomelor DA precum si a calitatii vietii la adulti cu DA moderat-severa. Dupixent a demonstrate un profil de siguranta favorabil la adulti cu DA moderat-severa.<\/p>\n
<\/span><\/span><\/p>\n
Dupixent is the first approved biological therapy for the treatment of moderate to severe atopic dermatitis. Dupixent is a human monoclonal antibody that specifically binds to the alpha receptor for interleukin 4 (IL4) and inhibits the cellular signaling of IL4\/IL13. Dupixent has demonstrated rapid and sustained improvements of signs and symptoms of AD as well as quality of life in adult with moderate to severe AD. Dupixent has demonstrated a favorable safety profile in adults with moderate to severe AD.<\/p>\n
\u2022 curs de Ecografie cutanat\u0103 \u2013 \u201eCortex Technologz\u201d (1996)
\u2022 curs de Ecografie cutanat\u0103 la Viena (1996)
\u2022 curs de Dermatoscopie la LKH Gratz (1996)
\u2022 curs Pulsed Dye Laser \u00een Viena (1996)
\u2022 curs de lasere (CO2, PDL, Nd Yag, Dioda) la Tel Aviv, Israel (1997)
\u2022 curs de lasere, CO2, Scanner \u00een Israel, Haifa (1997)
\u2022 curs Pulsed Dye Laser, Nd-Yag, Compania Coherent (2008)
\u2022 programul de Lasere \u00een Medicin\u0103 SPIRALMED (2010).
Autor al peste 200 de lucr\u0103ri publicate \u015fi comunicate din \u0163ar\u0103 \u015fi str\u0103in\u0103tate. Colaborator la redactarea manualului \u201cDermato-venerologie 2000\u201d.Consultant de specialitate pentru diverse afec\u0163iuni (dermatita atopic\u0103, psoriazis, etc.) \u00een cadrul cursurilor organizate de diverse companii farmaceutice.<\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n